People with HER2 positive metastatic breast cancer in Prince Edward Island (P.E.I.) will now be able to access a new treatment option through the P.E.I. Pharmacare Formulary.   Pertuzumab (Perjeta) and trastuzumab (Herceptin) have been approved for use in combination with a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within six months of receiving trastuzumab in the adjuvant setting.

"We are pleased to hear about the investment made by the Premier's Office into the P.E.I. Pharmacare Formulary and the province's decision to make the Perjeta-Herceptin Combo Pack available to HER2 positive metastatic breast patients," said Mr. Ronnie Miller, president and CEO, Roche Canada. "As a leader in oncology, Roche is committed to not only advancing science through our research, but also collaborating with key stakeholders within the healthcare system to help bring innovative treatments to patients who need it most.

For more details, go to: http://www.newswire.ca/en/story/1521769/prince-edward-island-adds-perjeta-herceptin-combo-pack-for-treatment-of-her2-positive-metastatic-breast-cancer-to-the-provincial-formulary